Le Lézard
Classified in: Health
Subjects: NPT, PER, WOM

Gynecologic Cancer Specialist Joins Capital Health Cancer Center


PENNINGTON, N.J., Nov. 12, 2019 /PRNewswire/ -- Dr. Joyce Varughese, a board certified, fellowship trained gynecologic oncologist, has joined Capital Health Surgical Group and is now part of the nationally accredited Capital Health Cancer Center, located at Capital Health Medical Center ? Hopewell. Dr. Varughese offers expertise in the most advanced treatments for all gynecologic cancers, including ovarian, uterine/endometrial, cervical, vulvar, and vaginal as well as pre-cancerous conditions in the female reproductive system.

Dr. Joyce Varughese

"We are always working to expand Capital Health's cancer care program, so we are excited to have Dr. Varughese join our team," said Dr. Cataldo Doria, medical director of Capital Health Cancer Center. "Her expertise fills an important surgical gap in the region and allows us to offer advanced gynecologic care for women in our area who might otherwise have to travel some distance to find the specialized services and expertise she provides."

Dr. Varughese completed her fellowship training in gynecologic oncology at Yale University and focuses on traditional and minimally invasive surgical approaches, including laparoscopic and robotic surgery using the da Vinci Surgical System.

From diagnosis through treatment, Dr. Varughese works closely with referring physicians and an integrated team of medical, surgical, radiation, and allied cancer specialists at Capital Health Cancer Center to develop a comprehensive, individualized plan of care.

"I was drawn to a career in gynecologic oncology in part because of the strong connections I make with my patients and their families," said Dr. Varughese. "I'm thrilled to be part of an organization that shares my patient-centered approach and my passion for advancing cancer care, particularly in an area of specialization that may not always be readily accessible for women."

Dr. Varughese is part of Capital Health Surgical Group, a multi-specialty surgical practice comprised of experienced surgeons who are experts in the surgical fields of acute care, bariatrics, breast, general, hepato-pancreato-biliary, thoracic, vascular and surgical critical care.

To make an appointment, call 609.537.6700 or visit www.capitalsurgical.org for more information.

About Capital Health Cancer Center

Capital Health Cancer Center, located at Capital Health Medical Center - Hopewell, is the area's most advanced provider of cancer treatment delivered by some of the most experienced medical experts. At our center, a team of physicians from related fields such as medical oncology, radiation oncology, gynecological oncology, neurosurgery, hepato-pancreato-biliary surgery, colorectal surgery, interventional GI and pulmonology, radiology, plastic and reconstructive surgery, thoracic surgery and other specialties collaborate and provide patients with a network of physicians trained in the most complex oncology issues. Capital Health is the only center in the region that offers advanced treatment options such as CyberKnife Radiosurgery, da Vinci Robotic Surgery, TrueBeam Linear Accelerator (traditional 3D conformal radiation therapy, intensity modulated radiation therapy, RapidArc radiotherapy, and stereotactic radiosurgery), high-dose-rate radiation therapy, advanced imaging technology (digital mammography, 3D mammography, molecular breast imaging, PET/CT, and 3T MRI), nuclear isotopes (SIR-spheres), and more. Visit capitalhealth.org/cancer to learn more.

 

SOURCE Capital Health Cancer Center


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: